%0 Journal Article
%T Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease
%A Deborah Lindquist
%A Lauren Ogawa
%J Archive of "Case Reports in Oncology".
%D 2018
%R 10.1159/000494264
%X Continuous therapy targeting human epidermal growth factor receptor 2 (HER2) is recommended until disease progression for patients with HER2-overexpressing (HER2+) metastatic breast cancer. Prolonged stable disease has been observed with such maintenance therapy using trastuzumab, but the frequency of these cases remains low. Whether combined maintenance therapy with two different HER2-targeted agents could improve the rates of durable progression-free survival compared with trastuzumab alone is under investigation
%K Lapatinib
%K Trastuzumab
%K HER2
%K Metastatic breast cancer
%K Inflammatory
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341317/